Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

Por Awada, A. H., Dumez, H., Hendlisz, A., Wolter, P., Besse-Hammer, T., Uttenreuther-Fischer, M., Stopfer, P., Fleischer, F., Piccart, M., Schöffski, P.
Publicado em 2012

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Por Schuler, Martin, Awada, Ahmad, Harter, Philipp, Canon, Jean Luc, Possinger, Kurt, Schmidt, Marcus, De Grève, Jacques, Neven, Patrick, Dirix, Luc, Jonat, Walter, Beckmann, Matthias W., Schütte, Jochen, Fasching, Peter A., Gottschalk, Nina, Besse-Hammer, Tatiana, Fleischer, Frank, Wind, Sven, Uttenreuther-Fischer, Martina, Piccart, Martine, Harbeck, Nadia
Publicado em 2012